Board Of Directors
Dr. Frank R. Jones, Chairman
Dr. Jones is a seasoned bio-tech entrepreneur. As the founder of Etubics, Dr. Jones has served as the Company’s Chairman of the Board of Director’s since its inception. He is the Principle Investigator on many of the company's National Institute of Health grants, which total over $7 million. From 1981 to 1996, Dr. Jones served as Founding Chairman and Chief Executive Officer of the publically traded medical device company IMRÉ CORPORATION (NASD: IMRE), which focused on immunoadsorption human treatments. From 1996 to 1998 Dr. Jones was Chairman and Chief Executive Officer of Scius Corporation, a private company. From 1998 to 2003 he consulted to the biotechnology industry and was the Managing Partner of Haidas Ranches, LLC a land development company. From 1983 until 1986, Dr. Jones was Director of the Immune Response Program of the Pacific Northwest Research Foundation in Seattle. Dr. Jones was a Researcher in the Department of Complement and Effector Biology at Memorial Sloan Kettering Cancer Center (“MSKCC”) in New York City from 1980 to 1981 and was a Research Associate in the Laboratory of Veterinary Oncology at MSKCC from 1981 to 1983. Dr. Jones holds a PhD degree from the University of Washington in Biological Structure/Cellular Immunology. He has 10 patents to his name and has published over 40 peer reviewed scientific papers.
Dr. John Abeles
Since 1992, Dr. Abeles has been the Founder, sole investor and General Partner of Northlea Partners Ltd., a private $30 million, venture and private capital, family partnership headquartered in Florida. He is also President of MedVest, Inc., a business and financial consulting firm, and has been instrumental in helping promulgate many early-stage medical and other companies. Dr. Abeles is a Managing Member of ProMed Capital LLC, a New York investment group promulgating Israeli medical venture companies and investments. In 1975 he was a Wall Street health-care analyst with Kidder Peabody until 1980 when he formed MedVest and later Northlea Partners. Prior to that, he practiced medicine in London before joining the pharmaceutical industry as a senior medical executive with Sterling Drug, Pfizer, Inc. and Revlon Health Care. Dr. Abeles received his medical degree as well as a degree in Pharmacology from the University of Birmingham, England.
Dr. Richard B. Gayle, III
Dr. Gayle was a founding board member of Sustainable Path Foundation and a Senior Scientist at Immunex Corporation for 16 years from 1986 to 2002. Dr. Gayle was involved in various projects while at Immunex and assisted the company by bringing a major product to the marketplace. He has had numerous peer-reviewed papers. Dr. Gayle received his PhD from the California Institute of Technology and graduated from Rice University with a degree in biochemistry.
Cohava Gelber, Ph.D., M.B.A
Dr. Gelber comes to the Company with over 20 years of biomedical research industry experience. She is presently the President and CEO of Caerus Discovery, LLC, a funded partnership with US and Japanese companies to develop new therapeutic antibodies for cancer, inflammatory and infectious diseases. Prior to Caerus, she was the Chief Scientific and Technology officer of ATCC, responsible for setting the strategy for science and the management of a large, diverse group of scientists focusing on microbiology, molecular biology, proteomics and bioinformatics in the area of biomarker discovery. At ATCC, Dr. Gelber also built a broad base to launch new research programs and spin-off for profit start-up companies. She also managed over 30 alliances with global academic institutes and biopharma. The collaborations focused on development of new proprietary technologies such as glycomics, microfluidity, biosensors and nanotechnology. While Vice President, Research and Development, at Mannkind Corporation (NASD: MNKD), Dr. Gelber was responsible for the entire non-clinical program in support of IND submissions for inhaled products and Phase II to II clinical trials. The focus of the company was diabetes and oncology. Dr. Gelber has over 30 scientific publications and 12 grated patents to her name. She received her Ph.D. in microbiology from the Weizmann Institute of Science and an MBA from Cornell University.
Phillip O’Riely, Esq.
Mr. O'Reilly has been the managing partner of O’Reilly, Marsh & Corteselli P.C., in New York, since the firm’s formation in 1986. He practices principally in the corporate area with an emphasis in corporate finance, securities law, real estate and estate planning. Mr. O’Reilly was a founding member of the firm of Doran, Buckley, Kremer, O’Reilly & Pieper and of its successor firm, Buckley, Kremer, O’Reilly, Pieper, Hoban & Marsh. Prior to Etubics, Mr. O'Reilly was employed at Dalaney & O'Reilly as well as Peat, Marwick, Mitchell & Co. Mr. O’Reilly is a member of the New York State and Nassau County Bar Associations and the President and a director of the Legal Aid Society of Suffolk County. He is a graduate of the University of Notre Dame and St. John’s Law School. Mr. O’Reilly holds a Master of Law in Taxation from New York University.